Oct. 28 - A startup's plan to challenge big pharma takes shape | Exact bets on cancer screening with Thrive deal

Facing vaccine doubts, US grapples with building confidence in coronavirus shots; Exact Sciences, challenging Illumina, to buy cancer screening company Thrive; Gilead's Veklury becomes first FDA-approved drug for COVID-19 View online | Signup | Forward

Marketing weekly Oct.​ 28,​ 2020 | This week's marketing news and insights for biopharma leaders   BROUGHT TO YOU BY — InCrowd A survey on the state of life sciences! Help us understand what's changing in life sciences by taking a brief survey. As a thank you, you will receive a $10 Starbucks e-gift card. Start now.   Note from the editor Next week, you will receive this newsletter under a different name. On Nov. 4, we are rebranding Marketing Weekly as Commercialization Weekly. We believe the name better reflects the stories featured in this newsletter, which covers how drugs are approved and sold as well as marketed. We will still report on the news you've come to expect: the latest on market competition, pharma and biotech company salesforces, drug pricing and advertising. The change will happen automatically next week. If you aren't interested in receiving this newsletter any longer, you can update your subscription here. Looking for more than just drug commercialization? Sign up for our Daily Dive here! Please let us know if you have any questions, and we hope to count you as a reader for years to come. Ned Pagliarulo Senior Editor, BioPharma Dive E-mail | Twitter EQRx builds cancer drug pipeline as plans to challenge big pharma take shape The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy. Facing vaccine doubts, US grapples with building confidence in coronavirus shots The CDC, for example, doesn't support vaccine mandates for healthcare workers or essential employees, an agency official told experts convened by the FDA last week. UPDATED Exact Sciences, challenging Illumina, to buy cancer screening company Thrive The deal for Thrive comes weeks after Illumina agreed to pay $8 billion for liquid biopsy developer Grail, and reflects expectations of a larger role for cancer tests. Sponsored Content by SAP Regulatory-driven material control with SAP Learn about material segmentation, a unique approach for characteristics-based planning and execution. UPDATED Gilead's Veklury becomes first FDA-approved drug for COVID-19 The U.S. regulator granted a full approval after allowing emergency use earlier this year. New results from an WHO study, however, raise questions about the drug's ultimate effectiveness. Read more news The Latest Developments in Gene Therapy In this Trendline, explore the latest in gene therapy development, as well as how investments from Roche and Novartis are shaping the market. Access Now From Our Library Trendline What You Need to Know About Oncology's Research Boom View all resources What We're Reading FiercePharma GSK's vaccines—especially Shingrix—typically drive growth. Amid COVID-19, they're a drag STAT Advocates urge Vertex to widen global access to cystic fibrosis drugs Reuters U.S. pharmacies attract new flu shot customers as coronavirus surges Suggest a story we should read Company Announcements Press releases from companies in your industry. Saama Launches Active Safety Analytics for Pharma (ASAP), Co-built with Gilead to Transform Safety Surveillance Press release from Saama Technologies BioIVT to Host Emerging Technologies in Diagnostics Symposium Press release from BioIVT Post a press release Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Marketing Weekly with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Marketing Weekly. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Marketing Weekly is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip